Jonas Lategahn, Dr. rer. nat.

Position: Postdoctoral fellow

Room no.: CP-02-133

Telephone no.: +49 (0)231 755 8834

Email: jonas.lategahn@tu-dortmund.de

Member of the group since: 12/2012

University Degree: Dr. rer. nat., Medicinal Chemistry and Chemical Biology, TU Dortmund University

 

Earlier positions: Master studies in Chemical Biology, TU Dortmund University; Bachelor studies at the Max-Planck-Institute of Molecular Physiology in the group of Andrey Antonchick on metal-free C–H bond functionalization.

Expertise: organic synthesis, cellular assays

Off-Lab activities (hobbies): parlor games, music, photography, indoor climbing

Research projects:

Drug resistant mutant variants of the the ErbB receptor tyrosine kinase family represent attractive targets with an urgent medical need in the targeted therapy of non-small cell lung cancer, which is a valuable treatment option as compared to harsh chemotherapy. This Medicinal Chemistry project has a strong focus on the development and evaluation of novel chemical entities as efficient inhibitors of mutant variants of EGFR and Her2. The work comprised screening, structure-based drug design, organic synthesis as well as evaluation of the synthesized compounds in cellular viability assays.

Publications:

  1. Lategahn, J.+; Keul, M.+; Rauh, D., Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer. Angew. Chem. Int. Ed. Engl. 2018, 57 (9), 2307-2313.
  2. Engel, J.+; Smith, S.+; Lategahn, J.; Tumbrink, H. L.; Goebel, L.; Becker, C.; Hennes, E.; Keul, M.; Unger, A.; Müller, H.; Baumann, M.; Schultz-Fademrecht, C.; Günther, G.; Hengstler, J. G.; Rauh, D., Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor. J. Med. Chem. 2017, 60 (18), 7725-7744.
  3. Günther, M.+; Lategahn, J.+; Juchum, M.; Döring, E.; Keul, M.; Engel, J.; Tumbrink, H. L.; Rauh, D.; Laufer, S., Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site. J. Med. Chem. 2017, 60 (13), 5613-5637.
  4. Tomassi, S.+; Lategahn, J.+; Engel, J.; Keul, M.; Tumbrink, H. L.; Ketzer, J.; Mühlenberg, T.; Baumann, M.; Schultz-Fademrecht, C.; Bauer, S.; Rauh, D., Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor. J. Med. Chem. 2017, 60 (6), 2361-2372.
  5. Engel, J.+; Becker, C.+; Lategahn, J.; Keul, M.; Ketzer, J.; Mühlenberg, T.; Kollipara, L.; Schultz-Fademrecht, C.; Zahedi, R. P.; Bauer, S.; Rauh, D., Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR. Angew. Chem. Int. Ed. Engl. 2016, 55 (36), 10909-10912.
  6. Engel, J.+; Lategahn, J.+; Rauh, D., Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer. ACS Med. Chem. Lett. 2016, 7 (1), 2-5.
  7. Engel, J.; Richters, A.; Getlik, M.; Tomassi, S.; Keul, M.; Termathe, M.; Lategahn, J.; Becker, C.; Mayer-Wrangowski, S.; Grütter, C.; Uhlenbrock, N.; Krüll, J.; Schaumann, N.; Eppmann, S.; Kibies, P.; Hoffgaard, F.; Heil, J.; Menninger, S.; Ortiz-Cuaran, S.; Heuckmann, J. M.; Tinnefeld, V.; Zahedi, R. P.; Sos, M. L.; Schultz-Fademrecht, C.; Thomas, R. K.; Kast, S. M.; Rauh, D., Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. J. Med. Chem. 2015, 58 (17), 6844-63.
  8. Samanta, R.+; Lategahn, J.+; Antonchick, A. P., Metal-free direct oxidative intermolecular diarylation of anilides at ambient temperature assisted by cascade selective formation of C-C and C-N bonds. Chemical Communications 2012, 48 (26), 3194-3196.
  9. Antonchick, A. P.; Samanta, R.; Kulikov, K.; Lategahn, J., Organocatalytic, Oxidative, Intramolecular C–H Bond Amination and Metal-free Cross-Amination of Unactivated Arenes at Ambient Temperature. Angew. Chem. Int. Ed. Engl. 2011, 50 (37), 8605-8608.